Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29431172 | 1.00 | HSD11B1 (0.40) | HSD11B1BRD4PAX8FLT3MAPT | |
| SCHEMBL29394664 | 0.84 | PIN1 (0.39) | HSD11B1BRD4PAX8MAPTALDH1A1 | |
| SCHEMBL29394672 | 0.84 | HSD11B1 (0.40) | HSD11B1BRD4PAX8FLT3MAPT | |
| SCHEMBL18662695 | 0.84 | PIN1 (0.39) | HSD11B1BRD4PAX8MAPTALDH1A1 | |
| SCHEMBL18662641 | 0.84 | HSD11B1 (0.40) | HSD11B1BRD4PAX8FLT3MAPT | |
| SCHEMBL23668186 | 0.83 | BRD4 (0.44) | HSD11B1BRD4FLT3ALDH1A1L3MBTL1 | |
| SCHEMBL30810135 | 0.83 | BRD4 (0.44) | HSD11B1BRD4FLT3ALDH1A1L3MBTL1 | |
| SCHEMBL18662673 | 0.82 | ABL1 (0.43) | HSD11B1BRD4PAX8MAPTALDH1A1 | |
| SCHEMBL29395224 | 0.82 | ABL1 (0.43) | HSD11B1BRD4PAX8MAPTALDH1A1 | |
| SCHEMBL29392114 | 0.82 | PIN1 (0.39) | HSD11B1BRD4PAX8MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319670-B2 | Compounds and methods for inhibiting JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-06-03 | — | — | US | disclosed |
| CN-111848586-B | Compounds and methods for inhibiting JAK | 迪哲(江苏)医药股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-3353168-B1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| EP-4219482-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-08-02 | — | — | EP | disclosed |
| US-20220119372-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2022-04-21 | — | — | US | disclosed |
| US-11247983-B2 | Compounds and methods for inhibiting JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-02-15 | — | — | US | disclosed |
| CN-111646980-B | Compounds and methods for inhibiting JAK | 迪哲(江苏)医药股份有限公司 | 2021-08-27 | — | — | CN | disclosed |
| CN-111606893-B | Compounds and methods for inhibiting JAK | 迪哲(江苏)医药股份有限公司 | 2021-05-04 | — | — | CN | disclosed |
| US-20210078981-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2021-03-18 | — | — | US | disclosed |
| CN-111848586-A | Compounds and methods for inhibiting JAK | 迪哲（江苏）医药有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-10167276-B2 | Compounds and methods for inhibiting JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2019-01-01 | — | — | US | disclosed |
| US-20170320857-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | ASTRAZENECA AB (SE) | 2017-11-09 | — | — | US | disclosed |
| US-20170320857-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | ASTRAZENECA AB (SE) | 2017-11-09 | — | — | US | disclosed |
| US-20170320857-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | ASTRAZENECA AB (SE) | 2017-11-09 | — | — | US | disclosed |
| US-9714236-B2 | Compounds and methods for inhibiting JAK | ASTRAZENECA AB (SE) | 2017-07-25 | — | — | US | disclosed |
| US-9714236-B2 | Compounds and methods for inhibiting JAK | ASTRAZENECA AB (SE) | 2017-07-25 | — | — | US | disclosed |
| US-9714236-B2 | Compounds and methods for inhibiting JAK | ASTRAZENECA AB (SE) | 2017-07-25 | — | — | US | disclosed |
| WO-2017050938-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | ASTRAZENECA AB (SE) | 2017-03-30 | — | — | WO | disclosed |
| US-20170088543-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | ASTRAZENECA AB (SE) | 2017-03-30 | — | — | US | disclosed |
| US-20170088543-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | ASTRAZENECA AB (SE) | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320857-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | JAK2, JAK3, JAK1 | HSD11B1 1204/4885BRD4 66/4885PAX8 3510/4885 |
| US-12319670-B2 | Compounds and methods for inhibiting JAK | JAK2, JAK3, JAK1 | HSD11B1 1204/4885BRD4 66/4885PAX8 3510/4885 |
| US-20220119372-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | JAK2, JAK3, JAK1 | HSD11B1 1204/4885BRD4 66/4885PAX8 3510/4885 |
| US-20210078981-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | JAK2, JAK3, JAK1 | HSD11B1 1204/4885BRD4 66/4885PAX8 3510/4885 |
| US-10167276-B2 | Compounds and methods for inhibiting JAK | JAK2, JAK3, JAK1 | HSD11B1 1204/4885BRD4 66/4885PAX8 3510/4885 |
| US-11247983-B2 | Compounds and methods for inhibiting JAK | JAK2, JAK3, JAK1 | HSD11B1 1204/4885BRD4 66/4885PAX8 3510/4885 |
| US-20170088543-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | JAK2, JAK3, JAK1 | HSD11B1 1204/4885BRD4 66/4885PAX8 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.